Baird Initiates Coverage On Intra-Cellular Therapies with Outperform Rating, Announces Price Target of $83
Portfolio Pulse from Benzinga Newsdesk
Baird analyst Joel Beatty has initiated coverage on Intra-Cellular Therapies (NASDAQ:ITCI) with an Outperform rating and set a price target of $83.
January 03, 2024 | 10:11 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Baird analyst Joel Beatty has initiated coverage on Intra-Cellular Therapies with an Outperform rating and a price target of $83, indicating a positive outlook for the stock.
The initiation of coverage by Baird with an Outperform rating typically suggests a bullish view on the stock's potential performance. The price target of $83 implies a significant upside from the current trading price, which could lead to increased investor interest and a potential rise in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 85
RELEVANCE 100